Global Insulin Biologics and Biosimilars Supply, Demand and Key Producers, 2023-2029
The global Insulin Biologics and Biosimilars market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
This report studies the global Insulin Biologics and Biosimilars demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Insulin Biologics and Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Insulin Biologics and Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Insulin Biologics and Biosimilars total market, 2018-2029, (USD Million)
Global Insulin Biologics and Biosimilars total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Insulin Biologics and Biosimilars total market, key domestic companies and share, (USD Million)
Global Insulin Biologics and Biosimilars revenue by player and market share 2018-2023, (USD Million)
Global Insulin Biologics and Biosimilars total market by Type, CAGR, 2018-2029, (USD Million)
Global Insulin Biologics and Biosimilars total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Insulin Biologics and Biosimilars market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Insulin Biologics and Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Insulin Biologics and Biosimilars Market, By Region:
1. How big is the global Insulin Biologics and Biosimilars market?
2. What is the demand of the global Insulin Biologics and Biosimilars market?
3. What is the year over year growth of the global Insulin Biologics and Biosimilars market?
4. What is the total value of the global Insulin Biologics and Biosimilars market?
5. Who are the major players in the global Insulin Biologics and Biosimilars market?
6. What are the growth factors driving the market demand?
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
This report studies the global Insulin Biologics and Biosimilars demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Insulin Biologics and Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Insulin Biologics and Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Insulin Biologics and Biosimilars total market, 2018-2029, (USD Million)
Global Insulin Biologics and Biosimilars total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Insulin Biologics and Biosimilars total market, key domestic companies and share, (USD Million)
Global Insulin Biologics and Biosimilars revenue by player and market share 2018-2023, (USD Million)
Global Insulin Biologics and Biosimilars total market by Type, CAGR, 2018-2029, (USD Million)
Global Insulin Biologics and Biosimilars total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Insulin Biologics and Biosimilars market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Insulin Biologics and Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Insulin Biologics and Biosimilars Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Insulin Biologics
- Insulin Biosimilars
- Hospital
- Retail Pharmacy
- Other
- Novo Nordisk
- Eli Lilly
- Sanofi
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- Geropharm
- Biocon
- Wockhardt
1. How big is the global Insulin Biologics and Biosimilars market?
2. What is the demand of the global Insulin Biologics and Biosimilars market?
3. What is the year over year growth of the global Insulin Biologics and Biosimilars market?
4. What is the total value of the global Insulin Biologics and Biosimilars market?
5. Who are the major players in the global Insulin Biologics and Biosimilars market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Insulin Biologics and Biosimilars Introduction
1.2 World Insulin Biologics and Biosimilars Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Insulin Biologics and Biosimilars Total Market by Region (by Headquarter Location)
1.3.1 World Insulin Biologics and Biosimilars Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.3 China Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.4 Europe Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.5 Japan Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.6 South Korea Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.7 ASEAN Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.8 India Insulin Biologics and Biosimilars Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Insulin Biologics and Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Insulin Biologics and Biosimilars Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.2 World Insulin Biologics and Biosimilars Consumption Value by Region
2.2.1 World Insulin Biologics and Biosimilars Consumption Value by Region (2018-2023)
2.2.2 World Insulin Biologics and Biosimilars Consumption Value Forecast by Region (2024-2029)
2.3 United States Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.4 China Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.5 Europe Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.6 Japan Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.7 South Korea Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.8 ASEAN Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.9 India Insulin Biologics and Biosimilars Consumption Value (2018-2029)
3 WORLD INSULIN BIOLOGICS AND BIOSIMILARS COMPANIES COMPETITIVE ANALYSIS
3.1 World Insulin Biologics and Biosimilars Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Insulin Biologics and Biosimilars Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Insulin Biologics and Biosimilars in 2022
3.2.3 Global Concentration Ratios (CR8) for Insulin Biologics and Biosimilars in 2022
3.3 Insulin Biologics and Biosimilars Company Evaluation Quadrant
3.4 Insulin Biologics and Biosimilars Market: Overall Company Footprint Analysis
3.4.1 Insulin Biologics and Biosimilars Market: Region Footprint
3.4.2 Insulin Biologics and Biosimilars Market: Company Product Type Footprint
3.4.3 Insulin Biologics and Biosimilars Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Insulin Biologics and Biosimilars Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Insulin Biologics and Biosimilars Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Insulin Biologics and Biosimilars Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Insulin Biologics and Biosimilars Consumption Value Comparison
4.2.1 United States VS China: Insulin Biologics and Biosimilars Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Insulin Biologics and Biosimilars Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Insulin Biologics and Biosimilars Companies and Market Share, 2018-2023
4.3.1 United States Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
4.4 China Based Companies Insulin Biologics and Biosimilars Revenue and Market Share, 2018-2023
4.4.1 China Based Insulin Biologics and Biosimilars Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
4.5 Rest of World Based Insulin Biologics and Biosimilars Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Insulin Biologics and Biosimilars Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Insulin Biologics
5.2.2 Insulin Biosimilars
5.3 Market Segment by Type
5.3.1 World Insulin Biologics and Biosimilars Market Size by Type (2018-2023)
5.3.2 World Insulin Biologics and Biosimilars Market Size by Type (2024-2029)
5.3.3 World Insulin Biologics and Biosimilars Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Insulin Biologics and Biosimilars Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Insulin Biologics and Biosimilars Market Size by Application (2018-2023)
6.3.2 World Insulin Biologics and Biosimilars Market Size by Application (2024-2029)
6.3.3 World Insulin Biologics and Biosimilars Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Novo Nordisk
7.1.1 Novo Nordisk Details
7.1.2 Novo Nordisk Major Business
7.1.3 Novo Nordisk Insulin Biologics and Biosimilars Product and Services
7.1.4 Novo Nordisk Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Novo Nordisk Recent Developments/Updates
7.1.6 Novo Nordisk Competitive Strengths & Weaknesses
7.2 Eli Lilly
7.2.1 Eli Lilly Details
7.2.2 Eli Lilly Major Business
7.2.3 Eli Lilly Insulin Biologics and Biosimilars Product and Services
7.2.4 Eli Lilly Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Eli Lilly Recent Developments/Updates
7.2.6 Eli Lilly Competitive Strengths & Weaknesses
7.3 Sanofi
7.3.1 Sanofi Details
7.3.2 Sanofi Major Business
7.3.3 Sanofi Insulin Biologics and Biosimilars Product and Services
7.3.4 Sanofi Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Sanofi Recent Developments/Updates
7.3.6 Sanofi Competitive Strengths & Weaknesses
7.4 Gan&Lee
7.4.1 Gan&Lee Details
7.4.2 Gan&Lee Major Business
7.4.3 Gan&Lee Insulin Biologics and Biosimilars Product and Services
7.4.4 Gan&Lee Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Gan&Lee Recent Developments/Updates
7.4.6 Gan&Lee Competitive Strengths & Weaknesses
7.5 Tonghua Dongbao
7.5.1 Tonghua Dongbao Details
7.5.2 Tonghua Dongbao Major Business
7.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Product and Services
7.5.4 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Tonghua Dongbao Recent Developments/Updates
7.5.6 Tonghua Dongbao Competitive Strengths & Weaknesses
7.6 United Laboratory
7.6.1 United Laboratory Details
7.6.2 United Laboratory Major Business
7.6.3 United Laboratory Insulin Biologics and Biosimilars Product and Services
7.6.4 United Laboratory Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 United Laboratory Recent Developments/Updates
7.6.6 United Laboratory Competitive Strengths & Weaknesses
7.7 Geropharm
7.7.1 Geropharm Details
7.7.2 Geropharm Major Business
7.7.3 Geropharm Insulin Biologics and Biosimilars Product and Services
7.7.4 Geropharm Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Geropharm Recent Developments/Updates
7.7.6 Geropharm Competitive Strengths & Weaknesses
7.8 Biocon
7.8.1 Biocon Details
7.8.2 Biocon Major Business
7.8.3 Biocon Insulin Biologics and Biosimilars Product and Services
7.8.4 Biocon Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Biocon Recent Developments/Updates
7.8.6 Biocon Competitive Strengths & Weaknesses
7.9 Wockhardt
7.9.1 Wockhardt Details
7.9.2 Wockhardt Major Business
7.9.3 Wockhardt Insulin Biologics and Biosimilars Product and Services
7.9.4 Wockhardt Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Wockhardt Recent Developments/Updates
7.9.6 Wockhardt Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Insulin Biologics and Biosimilars Industry Chain
8.2 Insulin Biologics and Biosimilars Upstream Analysis
8.3 Insulin Biologics and Biosimilars Midstream Analysis
8.4 Insulin Biologics and Biosimilars Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Insulin Biologics and Biosimilars Introduction
1.2 World Insulin Biologics and Biosimilars Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Insulin Biologics and Biosimilars Total Market by Region (by Headquarter Location)
1.3.1 World Insulin Biologics and Biosimilars Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.3 China Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.4 Europe Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.5 Japan Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.6 South Korea Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.7 ASEAN Insulin Biologics and Biosimilars Market Size (2018-2029)
1.3.8 India Insulin Biologics and Biosimilars Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Insulin Biologics and Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Insulin Biologics and Biosimilars Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.2 World Insulin Biologics and Biosimilars Consumption Value by Region
2.2.1 World Insulin Biologics and Biosimilars Consumption Value by Region (2018-2023)
2.2.2 World Insulin Biologics and Biosimilars Consumption Value Forecast by Region (2024-2029)
2.3 United States Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.4 China Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.5 Europe Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.6 Japan Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.7 South Korea Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.8 ASEAN Insulin Biologics and Biosimilars Consumption Value (2018-2029)
2.9 India Insulin Biologics and Biosimilars Consumption Value (2018-2029)
3 WORLD INSULIN BIOLOGICS AND BIOSIMILARS COMPANIES COMPETITIVE ANALYSIS
3.1 World Insulin Biologics and Biosimilars Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Insulin Biologics and Biosimilars Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Insulin Biologics and Biosimilars in 2022
3.2.3 Global Concentration Ratios (CR8) for Insulin Biologics and Biosimilars in 2022
3.3 Insulin Biologics and Biosimilars Company Evaluation Quadrant
3.4 Insulin Biologics and Biosimilars Market: Overall Company Footprint Analysis
3.4.1 Insulin Biologics and Biosimilars Market: Region Footprint
3.4.2 Insulin Biologics and Biosimilars Market: Company Product Type Footprint
3.4.3 Insulin Biologics and Biosimilars Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Insulin Biologics and Biosimilars Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Insulin Biologics and Biosimilars Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Insulin Biologics and Biosimilars Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Insulin Biologics and Biosimilars Consumption Value Comparison
4.2.1 United States VS China: Insulin Biologics and Biosimilars Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Insulin Biologics and Biosimilars Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Insulin Biologics and Biosimilars Companies and Market Share, 2018-2023
4.3.1 United States Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
4.4 China Based Companies Insulin Biologics and Biosimilars Revenue and Market Share, 2018-2023
4.4.1 China Based Insulin Biologics and Biosimilars Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
4.5 Rest of World Based Insulin Biologics and Biosimilars Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Insulin Biologics and Biosimilars Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Insulin Biologics
5.2.2 Insulin Biosimilars
5.3 Market Segment by Type
5.3.1 World Insulin Biologics and Biosimilars Market Size by Type (2018-2023)
5.3.2 World Insulin Biologics and Biosimilars Market Size by Type (2024-2029)
5.3.3 World Insulin Biologics and Biosimilars Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Insulin Biologics and Biosimilars Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Insulin Biologics and Biosimilars Market Size by Application (2018-2023)
6.3.2 World Insulin Biologics and Biosimilars Market Size by Application (2024-2029)
6.3.3 World Insulin Biologics and Biosimilars Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Novo Nordisk
7.1.1 Novo Nordisk Details
7.1.2 Novo Nordisk Major Business
7.1.3 Novo Nordisk Insulin Biologics and Biosimilars Product and Services
7.1.4 Novo Nordisk Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Novo Nordisk Recent Developments/Updates
7.1.6 Novo Nordisk Competitive Strengths & Weaknesses
7.2 Eli Lilly
7.2.1 Eli Lilly Details
7.2.2 Eli Lilly Major Business
7.2.3 Eli Lilly Insulin Biologics and Biosimilars Product and Services
7.2.4 Eli Lilly Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Eli Lilly Recent Developments/Updates
7.2.6 Eli Lilly Competitive Strengths & Weaknesses
7.3 Sanofi
7.3.1 Sanofi Details
7.3.2 Sanofi Major Business
7.3.3 Sanofi Insulin Biologics and Biosimilars Product and Services
7.3.4 Sanofi Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Sanofi Recent Developments/Updates
7.3.6 Sanofi Competitive Strengths & Weaknesses
7.4 Gan&Lee
7.4.1 Gan&Lee Details
7.4.2 Gan&Lee Major Business
7.4.3 Gan&Lee Insulin Biologics and Biosimilars Product and Services
7.4.4 Gan&Lee Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Gan&Lee Recent Developments/Updates
7.4.6 Gan&Lee Competitive Strengths & Weaknesses
7.5 Tonghua Dongbao
7.5.1 Tonghua Dongbao Details
7.5.2 Tonghua Dongbao Major Business
7.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Product and Services
7.5.4 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Tonghua Dongbao Recent Developments/Updates
7.5.6 Tonghua Dongbao Competitive Strengths & Weaknesses
7.6 United Laboratory
7.6.1 United Laboratory Details
7.6.2 United Laboratory Major Business
7.6.3 United Laboratory Insulin Biologics and Biosimilars Product and Services
7.6.4 United Laboratory Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 United Laboratory Recent Developments/Updates
7.6.6 United Laboratory Competitive Strengths & Weaknesses
7.7 Geropharm
7.7.1 Geropharm Details
7.7.2 Geropharm Major Business
7.7.3 Geropharm Insulin Biologics and Biosimilars Product and Services
7.7.4 Geropharm Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Geropharm Recent Developments/Updates
7.7.6 Geropharm Competitive Strengths & Weaknesses
7.8 Biocon
7.8.1 Biocon Details
7.8.2 Biocon Major Business
7.8.3 Biocon Insulin Biologics and Biosimilars Product and Services
7.8.4 Biocon Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Biocon Recent Developments/Updates
7.8.6 Biocon Competitive Strengths & Weaknesses
7.9 Wockhardt
7.9.1 Wockhardt Details
7.9.2 Wockhardt Major Business
7.9.3 Wockhardt Insulin Biologics and Biosimilars Product and Services
7.9.4 Wockhardt Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Wockhardt Recent Developments/Updates
7.9.6 Wockhardt Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Insulin Biologics and Biosimilars Industry Chain
8.2 Insulin Biologics and Biosimilars Upstream Analysis
8.3 Insulin Biologics and Biosimilars Midstream Analysis
8.4 Insulin Biologics and Biosimilars Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Insulin Biologics and Biosimilars Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Insulin Biologics and Biosimilars Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Insulin Biologics and Biosimilars Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Insulin Biologics and Biosimilars Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Insulin Biologics and Biosimilars Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Insulin Biologics and Biosimilars Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Insulin Biologics and Biosimilars Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Insulin Biologics and Biosimilars Players in 2022
Table 12. World Insulin Biologics and Biosimilars Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Insulin Biologics and Biosimilars Company Evaluation Quadrant
Table 14. Head Office of Key Insulin Biologics and Biosimilars Player
Table 15. Insulin Biologics and Biosimilars Market: Company Product Type Footprint
Table 16. Insulin Biologics and Biosimilars Market: Company Product Application Footprint
Table 17. Insulin Biologics and Biosimilars Mergers & Acquisitions Activity
Table 18. United States VS China Insulin Biologics and Biosimilars Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Insulin Biologics and Biosimilars Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
Table 21. United States Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 23. China Based Insulin Biologics and Biosimilars Companies, Headquarters (Province, Country)
Table 24. China Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 26. Rest of World Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 29. World Insulin Biologics and Biosimilars Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Insulin Biologics and Biosimilars Market Size by Type (2018-2023) & (USD Million)
Table 31. World Insulin Biologics and Biosimilars Market Size by Type (2024-2029) & (USD Million)
Table 32. World Insulin Biologics and Biosimilars Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Insulin Biologics and Biosimilars Market Size by Application (2018-2023) & (USD Million)
Table 34. World Insulin Biologics and Biosimilars Market Size by Application (2024-2029) & (USD Million)
Table 35. Novo Nordisk Basic Information, Area Served and Competitors
Table 36. Novo Nordisk Major Business
Table 37. Novo Nordisk Insulin Biologics and Biosimilars Product and Services
Table 38. Novo Nordisk Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Novo Nordisk Recent Developments/Updates
Table 40. Novo Nordisk Competitive Strengths & Weaknesses
Table 41. Eli Lilly Basic Information, Area Served and Competitors
Table 42. Eli Lilly Major Business
Table 43. Eli Lilly Insulin Biologics and Biosimilars Product and Services
Table 44. Eli Lilly Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Eli Lilly Recent Developments/Updates
Table 46. Eli Lilly Competitive Strengths & Weaknesses
Table 47. Sanofi Basic Information, Area Served and Competitors
Table 48. Sanofi Major Business
Table 49. Sanofi Insulin Biologics and Biosimilars Product and Services
Table 50. Sanofi Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Sanofi Recent Developments/Updates
Table 52. Sanofi Competitive Strengths & Weaknesses
Table 53. Gan&Lee Basic Information, Area Served and Competitors
Table 54. Gan&Lee Major Business
Table 55. Gan&Lee Insulin Biologics and Biosimilars Product and Services
Table 56. Gan&Lee Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Gan&Lee Recent Developments/Updates
Table 58. Gan&Lee Competitive Strengths & Weaknesses
Table 59. Tonghua Dongbao Basic Information, Area Served and Competitors
Table 60. Tonghua Dongbao Major Business
Table 61. Tonghua Dongbao Insulin Biologics and Biosimilars Product and Services
Table 62. Tonghua Dongbao Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Tonghua Dongbao Recent Developments/Updates
Table 64. Tonghua Dongbao Competitive Strengths & Weaknesses
Table 65. United Laboratory Basic Information, Area Served and Competitors
Table 66. United Laboratory Major Business
Table 67. United Laboratory Insulin Biologics and Biosimilars Product and Services
Table 68. United Laboratory Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. United Laboratory Recent Developments/Updates
Table 70. United Laboratory Competitive Strengths & Weaknesses
Table 71. Geropharm Basic Information, Area Served and Competitors
Table 72. Geropharm Major Business
Table 73. Geropharm Insulin Biologics and Biosimilars Product and Services
Table 74. Geropharm Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Geropharm Recent Developments/Updates
Table 76. Geropharm Competitive Strengths & Weaknesses
Table 77. Biocon Basic Information, Area Served and Competitors
Table 78. Biocon Major Business
Table 79. Biocon Insulin Biologics and Biosimilars Product and Services
Table 80. Biocon Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Biocon Recent Developments/Updates
Table 82. Wockhardt Basic Information, Area Served and Competitors
Table 83. Wockhardt Major Business
Table 84. Wockhardt Insulin Biologics and Biosimilars Product and Services
Table 85. Wockhardt Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 86. Global Key Players of Insulin Biologics and Biosimilars Upstream (Raw Materials)
Table 87. Insulin Biologics and Biosimilars Typical Customers
Table 1. World Insulin Biologics and Biosimilars Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Insulin Biologics and Biosimilars Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Insulin Biologics and Biosimilars Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Insulin Biologics and Biosimilars Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Insulin Biologics and Biosimilars Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Insulin Biologics and Biosimilars Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Insulin Biologics and Biosimilars Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Insulin Biologics and Biosimilars Players in 2022
Table 12. World Insulin Biologics and Biosimilars Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Insulin Biologics and Biosimilars Company Evaluation Quadrant
Table 14. Head Office of Key Insulin Biologics and Biosimilars Player
Table 15. Insulin Biologics and Biosimilars Market: Company Product Type Footprint
Table 16. Insulin Biologics and Biosimilars Market: Company Product Application Footprint
Table 17. Insulin Biologics and Biosimilars Mergers & Acquisitions Activity
Table 18. United States VS China Insulin Biologics and Biosimilars Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Insulin Biologics and Biosimilars Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
Table 21. United States Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 23. China Based Insulin Biologics and Biosimilars Companies, Headquarters (Province, Country)
Table 24. China Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 26. Rest of World Based Insulin Biologics and Biosimilars Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Insulin Biologics and Biosimilars Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Insulin Biologics and Biosimilars Revenue Market Share (2018-2023)
Table 29. World Insulin Biologics and Biosimilars Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Insulin Biologics and Biosimilars Market Size by Type (2018-2023) & (USD Million)
Table 31. World Insulin Biologics and Biosimilars Market Size by Type (2024-2029) & (USD Million)
Table 32. World Insulin Biologics and Biosimilars Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Insulin Biologics and Biosimilars Market Size by Application (2018-2023) & (USD Million)
Table 34. World Insulin Biologics and Biosimilars Market Size by Application (2024-2029) & (USD Million)
Table 35. Novo Nordisk Basic Information, Area Served and Competitors
Table 36. Novo Nordisk Major Business
Table 37. Novo Nordisk Insulin Biologics and Biosimilars Product and Services
Table 38. Novo Nordisk Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Novo Nordisk Recent Developments/Updates
Table 40. Novo Nordisk Competitive Strengths & Weaknesses
Table 41. Eli Lilly Basic Information, Area Served and Competitors
Table 42. Eli Lilly Major Business
Table 43. Eli Lilly Insulin Biologics and Biosimilars Product and Services
Table 44. Eli Lilly Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Eli Lilly Recent Developments/Updates
Table 46. Eli Lilly Competitive Strengths & Weaknesses
Table 47. Sanofi Basic Information, Area Served and Competitors
Table 48. Sanofi Major Business
Table 49. Sanofi Insulin Biologics and Biosimilars Product and Services
Table 50. Sanofi Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Sanofi Recent Developments/Updates
Table 52. Sanofi Competitive Strengths & Weaknesses
Table 53. Gan&Lee Basic Information, Area Served and Competitors
Table 54. Gan&Lee Major Business
Table 55. Gan&Lee Insulin Biologics and Biosimilars Product and Services
Table 56. Gan&Lee Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Gan&Lee Recent Developments/Updates
Table 58. Gan&Lee Competitive Strengths & Weaknesses
Table 59. Tonghua Dongbao Basic Information, Area Served and Competitors
Table 60. Tonghua Dongbao Major Business
Table 61. Tonghua Dongbao Insulin Biologics and Biosimilars Product and Services
Table 62. Tonghua Dongbao Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Tonghua Dongbao Recent Developments/Updates
Table 64. Tonghua Dongbao Competitive Strengths & Weaknesses
Table 65. United Laboratory Basic Information, Area Served and Competitors
Table 66. United Laboratory Major Business
Table 67. United Laboratory Insulin Biologics and Biosimilars Product and Services
Table 68. United Laboratory Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. United Laboratory Recent Developments/Updates
Table 70. United Laboratory Competitive Strengths & Weaknesses
Table 71. Geropharm Basic Information, Area Served and Competitors
Table 72. Geropharm Major Business
Table 73. Geropharm Insulin Biologics and Biosimilars Product and Services
Table 74. Geropharm Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Geropharm Recent Developments/Updates
Table 76. Geropharm Competitive Strengths & Weaknesses
Table 77. Biocon Basic Information, Area Served and Competitors
Table 78. Biocon Major Business
Table 79. Biocon Insulin Biologics and Biosimilars Product and Services
Table 80. Biocon Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Biocon Recent Developments/Updates
Table 82. Wockhardt Basic Information, Area Served and Competitors
Table 83. Wockhardt Major Business
Table 84. Wockhardt Insulin Biologics and Biosimilars Product and Services
Table 85. Wockhardt Insulin Biologics and Biosimilars Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 86. Global Key Players of Insulin Biologics and Biosimilars Upstream (Raw Materials)
Table 87. Insulin Biologics and Biosimilars Typical Customers
LIST OF FIGURES
Figure 1. Insulin Biologics and Biosimilars Picture
Figure 2. World Insulin Biologics and Biosimilars Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Insulin Biologics and Biosimilars Total Market Size (2018-2029) & (USD Million)
Figure 4. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 13. Insulin Biologics and Biosimilars Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 16. World Insulin Biologics and Biosimilars Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 18. China Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 23. India Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Insulin Biologics and Biosimilars by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Insulin Biologics and Biosimilars Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Insulin Biologics and Biosimilars Markets in 2022
Figure 27. United States VS China: Insulin Biologics and Biosimilars Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Insulin Biologics and Biosimilars Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Insulin Biologics and Biosimilars Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Insulin Biologics and Biosimilars Market Size Market Share by Type in 2022
Figure 31. Insulin Biologics
Figure 32. Insulin Biosimilars
Figure 33. World Insulin Biologics and Biosimilars Market Size Market Share by Type (2018-2029)
Figure 34. World Insulin Biologics and Biosimilars Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Insulin Biologics and Biosimilars Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Retail Pharmacy
Figure 38. Other
Figure 39. Insulin Biologics and Biosimilars Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Figure 1. Insulin Biologics and Biosimilars Picture
Figure 2. World Insulin Biologics and Biosimilars Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Insulin Biologics and Biosimilars Total Market Size (2018-2029) & (USD Million)
Figure 4. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Insulin Biologics and Biosimilars Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Insulin Biologics and Biosimilars Revenue (2018-2029) & (USD Million)
Figure 13. Insulin Biologics and Biosimilars Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 16. World Insulin Biologics and Biosimilars Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 18. China Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 23. India Insulin Biologics and Biosimilars Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Insulin Biologics and Biosimilars by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Insulin Biologics and Biosimilars Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Insulin Biologics and Biosimilars Markets in 2022
Figure 27. United States VS China: Insulin Biologics and Biosimilars Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Insulin Biologics and Biosimilars Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Insulin Biologics and Biosimilars Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Insulin Biologics and Biosimilars Market Size Market Share by Type in 2022
Figure 31. Insulin Biologics
Figure 32. Insulin Biosimilars
Figure 33. World Insulin Biologics and Biosimilars Market Size Market Share by Type (2018-2029)
Figure 34. World Insulin Biologics and Biosimilars Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Insulin Biologics and Biosimilars Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Retail Pharmacy
Figure 38. Other
Figure 39. Insulin Biologics and Biosimilars Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
